-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, July 28, June 30, the National Medical Insurance Administration announced the "2021 National Medical Insurance Drug Catalog Adjustment Work Plan" (hereinafter referred to as the "Plan") and "2021 National Medical Insurance Drug Catalog Adjustment Application Guidelines
.
" From July 1st, the 2021 National Medical Insurance Drug Catalogue Adjustment Application System was opened, and a new round of catalogue adjustment was officially launched
.
The results of this adjustment will be announced in October-November 2021, and will be implemented in January 2022
.
.
" From July 1st, the 2021 National Medical Insurance Drug Catalogue Adjustment Application System was opened, and a new round of catalogue adjustment was officially launched
.
The results of this adjustment will be announced in October-November 2021, and will be implemented in January 2022
.
Media report analysis
The first is to pay attention to the changes and highlights of the adjustment of the National Medical Insurance Drug List in 2021
.
China Economic Net released the "2021 Medical Insurance Drug Catalogue Adjustment Starts 4 Drugs to Be Included in the Application Scope", which stated that the adjustment clarified 4 application conditions for drugs not listed in the list, including January 1, 2016 to June 30, 2021.
During the period, new generic drugs approved by the State Drug Administration, drugs with major changes in indications or functional indications, drugs for the treatment of respiratory diseases related to new coronary pneumonia, and drugs included in the "National Essential Drug List (2018 Edition)"
.
At the same time, the "Plan" clarifies the application conditions for major changes in the indications or functional indications of drugs in the catalog and out of the catalog, and the key scope of the drugs to be transferred from the catalog
.
.
China Economic Net released the "2021 Medical Insurance Drug Catalogue Adjustment Starts 4 Drugs to Be Included in the Application Scope", which stated that the adjustment clarified 4 application conditions for drugs not listed in the list, including January 1, 2016 to June 30, 2021.
During the period, new generic drugs approved by the State Drug Administration, drugs with major changes in indications or functional indications, drugs for the treatment of respiratory diseases related to new coronary pneumonia, and drugs included in the "National Essential Drug List (2018 Edition)"
.
At the same time, the "Plan" clarifies the application conditions for major changes in the indications or functional indications of drugs in the catalog and out of the catalog, and the key scope of the drugs to be transferred from the catalog
.
The "National Medical Insurance Drug Catalog Adjustment Started, and Four Types of Drugs Can Be Reported and Transferred" released by the Sina number "People's Microwatch" stated that this year is the second year of the implementation of the declaration system.
Compared with previous years, the scope of review is more scientific and accurate
.
In the review stage, it is planned to further increase the communication link with relevant enterprises, listen to the opinions and suggestions of enterprises more fully, answer questions in a timely manner, and improve transparency
.
Compared with previous years, the scope of review is more scientific and accurate
.
In the review stage, it is planned to further increase the communication link with relevant enterprises, listen to the opinions and suggestions of enterprises more fully, answer questions in a timely manner, and improve transparency
.
The second is to analyze the difference between the official draft of the "Plan" and the draft for comments
.
The "Announcement of the Medical Insurance Catalog Adjustment Plan: Increased pharmaceutical company symposiums and no longer publishes the original price of the products" released by the WeChat public account "Health and Knowledge Bureau" stated that the "plan" will be added from June to July this year and will be adopted through seminars and other forms Fully soliciting opinions from relevant parties reflects the positive attitude of the National Medical Insurance Administration to open its doors and accept opinions
.
In the interpretation of the National Medical Insurance Administration, this initiative is regarded as one of the efforts to "improve the participation of all parties
.
"
.
The "Announcement of the Medical Insurance Catalog Adjustment Plan: Increased pharmaceutical company symposiums and no longer publishes the original price of the products" released by the WeChat public account "Health and Knowledge Bureau" stated that the "plan" will be added from June to July this year and will be adopted through seminars and other forms Fully soliciting opinions from relevant parties reflects the positive attitude of the National Medical Insurance Administration to open its doors and accept opinions
.
In the interpretation of the National Medical Insurance Administration, this initiative is regarded as one of the efforts to "improve the participation of all parties
.
"
At the same time, it was proposed in the draft for comments that the drug price must be disclosed for the products that have been declared to join the medical insurance and passed the formal review this year.
However, in the final version of the "Plan", the "publication of the original price" requirement was removed and replaced by the disclosure of basic drug information and validity.
Information about sex, safety, innovation, and fairness
.
However, in the final version of the "Plan", the "publication of the original price" requirement was removed and replaced by the disclosure of basic drug information and validity.
Information about sex, safety, innovation, and fairness
.
In addition, the National Medical Insurance Bureau also revealed in the interpretation that "sky-priced drugs" and "magic medicine" will not appear in this round of medical insurance negotiations
.
Earlier, there was news among foreign-funded pharmaceutical companies that varieties with an annual treatment cost of more than 500,000 yuan would not be included in this round of medical insurance price negotiations, but the National Medical Insurance Bureau did not explicitly mention this price red line in the official interpretation
.
.
Earlier, there was news among foreign-funded pharmaceutical companies that varieties with an annual treatment cost of more than 500,000 yuan would not be included in this round of medical insurance price negotiations, but the National Medical Insurance Bureau did not explicitly mention this price red line in the official interpretation
.
The third is to pay attention to the approval of a number of new drugs before the release of the "Plan"
.
According to the "2021 Medical Insurance Catalog Adjustment Plan Finalized by China Business News, a variety of new drugs were approved for listing" said that in June, a number of new drugs were approved, covering antiviral, antitumor, and rare disease treatment drugs
.
A number of relevant pharmaceutical companies stated that they have plans to include their new drug declarations in the 2021 medical insurance catalogue
.
However, with so many new drugs being approved for listing, pharmaceutical companies will face fierce competition with limited medical insurance funds
.
.
According to the "2021 Medical Insurance Catalog Adjustment Plan Finalized by China Business News, a variety of new drugs were approved for listing" said that in June, a number of new drugs were approved, covering antiviral, antitumor, and rare disease treatment drugs
.
A number of relevant pharmaceutical companies stated that they have plans to include their new drug declarations in the 2021 medical insurance catalogue
.
However, with so many new drugs being approved for listing, pharmaceutical companies will face fierce competition with limited medical insurance funds
.
The fourth is to analyze the impact of catalog adjustments on the pharmaceutical industry and domestic innovative drugs
.
According to a related article published by the Health Times client, Li Yan, a representative of the National People's Congress and president of Qilu Pharmaceutical, said that national centralized procurement and medical insurance negotiations have made good medicines available and affordable to more patients
.
In the long run, the implementation and normalization of the two policies will profoundly affect the transformation of the pharmaceutical industry and the reshaping of the market structure.
Pharmaceutical companies must increase investment in R&D and innovation if they want to maintain their competitive advantages.
The relevant policies objectively force pharmaceutical companies Carry out "source innovation"
.
The medical insurance negotiation provides practical support for innovative drugs from the payment level, solves the problems of drug market access and hospital access, and will provide a stable and clear market for innovative products and innovative companies, and increase the confidence and confidence of pharmaceutical companies to vigorously carry out scientific and technological innovation.
Determined
.
.
According to a related article published by the Health Times client, Li Yan, a representative of the National People's Congress and president of Qilu Pharmaceutical, said that national centralized procurement and medical insurance negotiations have made good medicines available and affordable to more patients
.
In the long run, the implementation and normalization of the two policies will profoundly affect the transformation of the pharmaceutical industry and the reshaping of the market structure.
Pharmaceutical companies must increase investment in R&D and innovation if they want to maintain their competitive advantages.
The relevant policies objectively force pharmaceutical companies Carry out "source innovation"
.
The medical insurance negotiation provides practical support for innovative drugs from the payment level, solves the problems of drug market access and hospital access, and will provide a stable and clear market for innovative products and innovative companies, and increase the confidence and confidence of pharmaceutical companies to vigorously carry out scientific and technological innovation.
Determined
.
According to the "New Round of Medical Insurance Drug Catalog Adjustment Started, Can Domestic Innovative Drugs Usher in Spring" published by China Business Daily, the new round of national medical insurance drug catalog adjustment is considered by some industry players to be a new opportunity for the development of domestic innovative drugs
.
Some experts said that, unlike the national organization of centralized drug procurement, the medical insurance drug catalogue is adjusted more for drugs with high clinical value and high demand, among which innovative drugs have attracted much attention
.
In recent years, Chinese pharmaceutical companies have accelerated the development of innovative drugs, and domestic innovative drugs may usher in the spring of development with the help of medical insurance catalog adjustments
.
.
Some experts said that, unlike the national organization of centralized drug procurement, the medical insurance drug catalogue is adjusted more for drugs with high clinical value and high demand, among which innovative drugs have attracted much attention
.
In recent years, Chinese pharmaceutical companies have accelerated the development of innovative drugs, and domestic innovative drugs may usher in the spring of development with the help of medical insurance catalog adjustments
.
Fifth, it is predicted that the medical insurance catalog may involve the adjustment of drugs and the extent of price reductions
.
According to the "Choice between Entry and Exit, 2021 Medical Insurance Catalogue Adjustments" published by the WeChat public account "Medicine Observer Network", it is predicted that the number of innovative drugs (not including proprietary Chinese medicines) in the 2021 version of the catalogue is expected to be large
.
Products that did not enter the 2019 and 2020 medical insurance catalogues do not have advantages in terms of price.
Therefore, it is predicted that the final drugs imported into the 2021 catalogue will be mostly innovative drugs and innovative biological preparations, as well as some Chinese patent medicines and old products.
Less
.
At the same time, the average price drop is expected to exceed 50%
.
( Liu Yang, Public Opinion Monitoring Center of China Health Media Group)
.
According to the "Choice between Entry and Exit, 2021 Medical Insurance Catalogue Adjustments" published by the WeChat public account "Medicine Observer Network", it is predicted that the number of innovative drugs (not including proprietary Chinese medicines) in the 2021 version of the catalogue is expected to be large
.
Products that did not enter the 2019 and 2020 medical insurance catalogues do not have advantages in terms of price.
Therefore, it is predicted that the final drugs imported into the 2021 catalogue will be mostly innovative drugs and innovative biological preparations, as well as some Chinese patent medicines and old products.
Less
.
At the same time, the average price drop is expected to exceed 50%
.
( Liu Yang, Public Opinion Monitoring Center of China Health Media Group)
Medical Network, July 28, June 30, the National Medical Insurance Administration announced the "2021 National Medical Insurance Drug Catalog Adjustment Work Plan" (hereinafter referred to as the "Plan") and "2021 National Medical Insurance Drug Catalog Adjustment Application Guidelines
.
" From July 1st, the 2021 National Medical Insurance Drug Catalogue Adjustment Application System was opened, and a new round of catalogue adjustment was officially launched
.
The results of this adjustment will be announced in October-November 2021, and will be implemented in January 2022
.
.
" From July 1st, the 2021 National Medical Insurance Drug Catalogue Adjustment Application System was opened, and a new round of catalogue adjustment was officially launched
.
The results of this adjustment will be announced in October-November 2021, and will be implemented in January 2022
.
Media report analysis
The first is to pay attention to the changes and highlights of the adjustment of the National Medical Insurance Drug List in 2021
.
China Economic Net released the "2021 Medical Insurance Drug Catalogue Adjustment Starts 4 Drugs to Be Included in the Application Scope", which stated that the adjustment clarified 4 application conditions for drugs not listed in the list, including January 1, 2016 to June 30, 2021.
During the period, new generic drugs approved by the State Drug Administration, drugs with major changes in indications or functional indications, drugs for the treatment of respiratory diseases related to new coronary pneumonia, and drugs included in the "National Essential Drug List (2018 Edition)"
.
At the same time, the "Plan" clarifies the application conditions for major changes in the indications or functional indications of drugs in the catalog and out of the catalog, and the key scope of the drugs to be transferred from the catalog
.
.
China Economic Net released the "2021 Medical Insurance Drug Catalogue Adjustment Starts 4 Drugs to Be Included in the Application Scope", which stated that the adjustment clarified 4 application conditions for drugs not listed in the list, including January 1, 2016 to June 30, 2021.
During the period, new generic drugs approved by the State Drug Administration, drugs with major changes in indications or functional indications, drugs for the treatment of respiratory diseases related to new coronary pneumonia, and drugs included in the "National Essential Drug List (2018 Edition)"
.
At the same time, the "Plan" clarifies the application conditions for major changes in the indications or functional indications of drugs in the catalog and out of the catalog, and the key scope of the drugs to be transferred from the catalog
.
The "National Medical Insurance Drug Catalog Adjustment Started, and Four Types of Drugs Can Be Reported and Transferred" released by the Sina number "People's Microwatch" stated that this year is the second year of the implementation of the declaration system.
Compared with previous years, the scope of review is more scientific and accurate
.
In the review stage, it is planned to further increase the communication link with relevant enterprises, listen to the opinions and suggestions of enterprises more fully, answer questions in a timely manner, and improve transparency
.
Compared with previous years, the scope of review is more scientific and accurate
.
In the review stage, it is planned to further increase the communication link with relevant enterprises, listen to the opinions and suggestions of enterprises more fully, answer questions in a timely manner, and improve transparency
.
The second is to analyze the difference between the official draft of the "Plan" and the draft for comments
.
The "Announcement of the Medical Insurance Catalog Adjustment Plan: Increased pharmaceutical company symposiums and no longer publishes the original price of the products" released by the WeChat public account "Health and Knowledge Bureau" stated that the "plan" will be added from June to July this year and will be adopted through seminars and other forms Fully soliciting opinions from relevant parties reflects the positive attitude of the National Medical Insurance Administration to open its doors and accept opinions
.
In the interpretation of the National Medical Insurance Administration, this initiative is regarded as one of the efforts to "improve the participation of all parties
.
"
.
The "Announcement of the Medical Insurance Catalog Adjustment Plan: Increased pharmaceutical company symposiums and no longer publishes the original price of the products" released by the WeChat public account "Health and Knowledge Bureau" stated that the "plan" will be added from June to July this year and will be adopted through seminars and other forms Fully soliciting opinions from relevant parties reflects the positive attitude of the National Medical Insurance Administration to open its doors and accept opinions
.
In the interpretation of the National Medical Insurance Administration, this initiative is regarded as one of the efforts to "improve the participation of all parties
.
"
At the same time, it was proposed in the draft for comments that the drug price must be disclosed for the products that have been declared to join the medical insurance and passed the formal review this year.
However, in the final version of the "Plan", the "publication of the original price" requirement was removed and replaced by the disclosure of basic drug information and validity.
Information about sex, safety, innovation, and fairness
.
However, in the final version of the "Plan", the "publication of the original price" requirement was removed and replaced by the disclosure of basic drug information and validity.
Information about sex, safety, innovation, and fairness
.
In addition, the National Medical Insurance Bureau also revealed in the interpretation that "sky-priced drugs" and "magic medicine" will not appear in this round of medical insurance negotiations
.
Earlier, there was news among foreign-funded pharmaceutical companies that varieties with an annual treatment cost of more than 500,000 yuan would not be included in this round of medical insurance price negotiations, but the National Medical Insurance Bureau did not explicitly mention this price red line in the official interpretation
.
.
Earlier, there was news among foreign-funded pharmaceutical companies that varieties with an annual treatment cost of more than 500,000 yuan would not be included in this round of medical insurance price negotiations, but the National Medical Insurance Bureau did not explicitly mention this price red line in the official interpretation
.
The third is to pay attention to the approval of a number of new drugs before the release of the "Plan"
.
According to the "2021 Medical Insurance Catalog Adjustment Plan Finalized by China Business News, a variety of new drugs were approved for listing" said that in June, a number of new drugs were approved, covering antiviral, antitumor, and rare disease treatment drugs
.
A number of relevant pharmaceutical companies stated that they have plans to include their new drug declarations in the 2021 medical insurance catalogue
.
However, with so many new drugs being approved for listing, pharmaceutical companies will face fierce competition with limited medical insurance funds
.
.
According to the "2021 Medical Insurance Catalog Adjustment Plan Finalized by China Business News, a variety of new drugs were approved for listing" said that in June, a number of new drugs were approved, covering antiviral, antitumor, and rare disease treatment drugs
.
A number of relevant pharmaceutical companies stated that they have plans to include their new drug declarations in the 2021 medical insurance catalogue
.
However, with so many new drugs being approved for listing, pharmaceutical companies will face fierce competition with limited medical insurance funds
.
The fourth is to analyze the impact of catalog adjustments on the pharmaceutical industry and domestic innovative drugs
.
According to a related article published by the Health Times client, Li Yan, a representative of the National People's Congress and president of Qilu Pharmaceutical, said that national centralized procurement and medical insurance negotiations have made good medicines available and affordable to more patients
.
In the long run, the implementation and normalization of the two policies will profoundly affect the transformation of the pharmaceutical industry and the reshaping of the market structure.
Pharmaceutical companies must increase investment in R&D and innovation if they want to maintain their competitive advantages.
The relevant policies objectively force pharmaceutical companies Carry out "source innovation"
.
The medical insurance negotiation provides practical support for innovative drugs from the payment level, solves the problems of drug market access and hospital access, and will provide a stable and clear market for innovative products and innovative companies, and increase the confidence and confidence of pharmaceutical companies to vigorously carry out scientific and technological innovation.
Determined
.
.
According to a related article published by the Health Times client, Li Yan, a representative of the National People's Congress and president of Qilu Pharmaceutical, said that national centralized procurement and medical insurance negotiations have made good medicines available and affordable to more patients
.
In the long run, the implementation and normalization of the two policies will profoundly affect the transformation of the pharmaceutical industry and the reshaping of the market structure.
Pharmaceutical companies must increase investment in R&D and innovation if they want to maintain their competitive advantages.
The relevant policies objectively force pharmaceutical companies Carry out "source innovation"
.
The medical insurance negotiation provides practical support for innovative drugs from the payment level, solves the problems of drug market access and hospital access, and will provide a stable and clear market for innovative products and innovative companies, and increase the confidence and confidence of pharmaceutical companies to vigorously carry out scientific and technological innovation.
Determined
.
According to the "New Round of Medical Insurance Drug Catalog Adjustment Started, Can Domestic Innovative Drugs Usher in Spring" published by China Business Daily, the new round of national medical insurance drug catalog adjustment is considered by some industry players to be a new opportunity for the development of domestic innovative drugs
.
Some experts said that, unlike the national organization of centralized drug procurement, the medical insurance drug catalogue is adjusted more for drugs with high clinical value and high demand, among which innovative drugs have attracted much attention
.
In recent years, Chinese pharmaceutical companies have accelerated the development of innovative drugs, and domestic innovative drugs may usher in the spring of development with the help of medical insurance catalog adjustments
.
.
Some experts said that, unlike the national organization of centralized drug procurement, the medical insurance drug catalogue is adjusted more for drugs with high clinical value and high demand, among which innovative drugs have attracted much attention
.
In recent years, Chinese pharmaceutical companies have accelerated the development of innovative drugs, and domestic innovative drugs may usher in the spring of development with the help of medical insurance catalog adjustments
.
Fifth, it is predicted that the medical insurance catalog may involve the adjustment of drugs and the extent of price reductions
.
According to the "Choice between Entry and Exit, 2021 Medical Insurance Catalogue Adjustments" published by the WeChat public account "Medicine Observer Network", it is predicted that the number of innovative drugs (not including proprietary Chinese medicines) in the 2021 version of the catalogue is expected to be large
.
Products that did not enter the 2019 and 2020 medical insurance catalogues do not have advantages in terms of price.
Therefore, it is predicted that the final drugs imported into the 2021 catalogue will be mostly innovative drugs and innovative biological preparations, as well as some Chinese patent medicines and old products.
Less
.
At the same time, the average price drop is expected to exceed 50%
.
( Liu Yang, Public Opinion Monitoring Center of China Health Media Group)
.
According to the "Choice between Entry and Exit, 2021 Medical Insurance Catalogue Adjustments" published by the WeChat public account "Medicine Observer Network", it is predicted that the number of innovative drugs (not including proprietary Chinese medicines) in the 2021 version of the catalogue is expected to be large
.
Products that did not enter the 2019 and 2020 medical insurance catalogues do not have advantages in terms of price.
Therefore, it is predicted that the final drugs imported into the 2021 catalogue will be mostly innovative drugs and innovative biological preparations, as well as some Chinese patent medicines and old products.
Less
.
At the same time, the average price drop is expected to exceed 50%
.
( Liu Yang, Public Opinion Monitoring Center of China Health Media Group)
Medical Network, July 28, June 30, the National Medical Insurance Administration announced the "2021 National Medical Insurance Drug Catalog Adjustment Work Plan" (hereinafter referred to as the "Plan") and "2021 National Medical Insurance Drug Catalog Adjustment Application Guidelines
.
" From July 1st, the 2021 National Medical Insurance Drug Catalogue Adjustment Application System was opened, and a new round of catalogue adjustment was officially launched
.
The results of this adjustment will be announced in October-November 2021, and will be implemented in January 2022
.
.
" From July 1st, the 2021 National Medical Insurance Drug Catalogue Adjustment Application System was opened, and a new round of catalogue adjustment was officially launched
.
The results of this adjustment will be announced in October-November 2021, and will be implemented in January 2022
.
Media report analysis
Media report analysis The first is to pay attention to the changes and highlights of the adjustment of the National Medical Insurance Drug List in 2021
.
China Economic Net released the "2021 Medical Insurance Drug Catalogue Adjustment Starts 4 Drugs to Be Included in the Application Scope", which stated that the adjustment clarified 4 application conditions for drugs not listed in the list, including January 1, 2016 to June 30, 2021.
During the period, new generic drugs approved by the State Drug Administration, drugs with major changes in indications or functional indications, drugs for the treatment of respiratory diseases related to new coronary pneumonia, and drugs included in the "National Essential Drug List (2018 Edition)"
.
At the same time, the "Plan" clarifies the application conditions for major changes in the indications or functional indications of drugs in the catalog and out of the catalog, and the key scope of the drugs to be transferred from the catalog
.
.
China Economic Net released the "2021 Medical Insurance Drug Catalogue Adjustment Starts 4 Drugs to Be Included in the Application Scope", which stated that the adjustment clarified 4 application conditions for drugs not listed in the list, including January 1, 2016 to June 30, 2021.
During the period, new generic drugs approved by the State Drug Administration, drugs with major changes in indications or functional indications, drugs for the treatment of respiratory diseases related to new coronary pneumonia, and drugs included in the "National Essential Drug List (2018 Edition)"
.
At the same time, the "Plan" clarifies the application conditions for major changes in the indications or functional indications of drugs in the catalog and out of the catalog, and the key scope of the drugs to be transferred from the catalog
.
The "National Medical Insurance Drug Catalog Adjustment Started, and Four Types of Drugs Can Be Reported and Transferred" released by the Sina number "People's Microwatch" stated that this year is the second year of the implementation of the declaration system.
Compared with previous years, the scope of review is more scientific and accurate
.
In the review stage, it is planned to further increase the communication link with relevant enterprises, listen to the opinions and suggestions of enterprises more fully, answer questions in a timely manner, and improve transparency
.
Compared with previous years, the scope of review is more scientific and accurate
.
In the review stage, it is planned to further increase the communication link with relevant enterprises, listen to the opinions and suggestions of enterprises more fully, answer questions in a timely manner, and improve transparency
.
The second is to analyze the difference between the official draft of the "Plan" and the draft for comments
.
The "Announcement of the Medical Insurance Catalog Adjustment Plan: Increased pharmaceutical company symposiums and no longer publishes the original price of the products" released by the WeChat public account "Health and Knowledge Bureau" stated that the "plan" will be added from June to July this year and will be adopted through seminars and other forms Fully soliciting opinions from relevant parties reflects the positive attitude of the National Medical Insurance Administration to open its doors and accept opinions
.
In the interpretation of the National Medical Insurance Administration, this initiative is regarded as one of the efforts to "improve the participation of all parties
.
"
.
The "Announcement of the Medical Insurance Catalog Adjustment Plan: Increased pharmaceutical company symposiums and no longer publishes the original price of the products" released by the WeChat public account "Health and Knowledge Bureau" stated that the "plan" will be added from June to July this year and will be adopted through seminars and other forms Fully soliciting opinions from relevant parties reflects the positive attitude of the National Medical Insurance Administration to open its doors and accept opinions
.
In the interpretation of the National Medical Insurance Administration, this initiative is regarded as one of the efforts to "improve the participation of all parties
.
"
At the same time, it was proposed in the draft for comments that the drug price must be disclosed for the products that have been declared to join the medical insurance and passed the formal review this year.
However, in the final version of the "Plan", the "publication of the original price" requirement was removed and replaced by the disclosure of basic drug information and validity.
Information about sex, safety, innovation, and fairness
.
However, in the final version of the "Plan", the "publication of the original price" requirement was removed and replaced by the disclosure of basic drug information and validity.
Information about sex, safety, innovation, and fairness
.
In addition, the National Medical Insurance Bureau also revealed in the interpretation that "sky-priced drugs" and "magic medicine" will not appear in this round of medical insurance negotiations
.
Earlier, there was news among foreign-funded pharmaceutical companies that varieties with an annual treatment cost of more than 500,000 yuan would not be included in this round of medical insurance price negotiations, but the National Medical Insurance Bureau did not explicitly mention this price red line in the official interpretation
.
.
Earlier, there was news among foreign-funded pharmaceutical companies that varieties with an annual treatment cost of more than 500,000 yuan would not be included in this round of medical insurance price negotiations, but the National Medical Insurance Bureau did not explicitly mention this price red line in the official interpretation
.
The third is to pay attention to the approval of a number of new drugs before the release of the "Plan"
.
According to the "2021 Medical Insurance Catalog Adjustment Plan Finalized by China Business News, a variety of new drugs were approved for listing" said that in June, a number of new drugs were approved, covering antiviral, antitumor, and rare disease treatment drugs
.
A number of relevant pharmaceutical companies stated that they have plans to include their new drug declarations in the 2021 medical insurance catalogue
.
However, with so many new drugs being approved for listing, pharmaceutical companies will face fierce competition with limited medical insurance funds
.
.
According to the "2021 Medical Insurance Catalog Adjustment Plan Finalized by China Business News, a variety of new drugs were approved for listing" said that in June, a number of new drugs were approved, covering antiviral, antitumor, and rare disease treatment drugs
.
A number of relevant pharmaceutical companies stated that they have plans to include their new drug declarations in the 2021 medical insurance catalogue
.
However, with so many new drugs being approved for listing, pharmaceutical companies will face fierce competition with limited medical insurance funds
.
The fourth is to analyze the impact of catalog adjustments on the pharmaceutical industry and domestic innovative drugs
.
According to a related article published by the Health Times client, Li Yan, a representative of the National People's Congress and president of Qilu Pharmaceutical, said that national centralized procurement and medical insurance negotiations have made good medicines available and affordable to more patients
.
In the long run, the implementation and normalization of the two policies will profoundly affect the transformation of the pharmaceutical industry and the reshaping of the market structure.
Pharmaceutical companies must increase investment in R&D and innovation if they want to maintain their competitive advantages.
The relevant policies objectively force pharmaceutical companies Carry out "source innovation"
.
The medical insurance negotiation provides practical support for innovative drugs from the payment level, solves the problems of drug market access and hospital access, and will provide a stable and clear market for innovative products and innovative companies, and increase the confidence and confidence of pharmaceutical companies to vigorously carry out scientific and technological innovation.
Determined
.
Pharmaceutical medicine pharmaceutical companies business enterprises Hospital Hospital Hospital.
According to a related article published by the Health Times client, Li Yan, a representative of the National People's Congress and president of Qilu Pharmaceutical, said that national centralized procurement and medical insurance negotiations have made good medicines available and affordable to more patients
.
In the long run, the implementation and normalization of the two policies will profoundly affect the transformation of the pharmaceutical industry and the reshaping of the market structure.
Pharmaceutical companies must increase investment in R&D and innovation if they want to maintain their competitive advantages.
The relevant policies objectively force pharmaceutical companies Carry out "source innovation"
.
The medical insurance negotiation provides practical support for innovative drugs from the payment level, solves the problems of drug market access and hospital access, and will provide a stable and clear market for innovative products and innovative companies, and increase the confidence and confidence of pharmaceutical companies to vigorously carry out scientific and technological innovation.
Determined
.
According to the "New Round of Medical Insurance Drug Catalog Adjustment Started, Can Domestic Innovative Drugs Usher in Spring" published by China Business Daily, the new round of national medical insurance drug catalog adjustment is considered by some industry players to be a new opportunity for the development of domestic innovative drugs
.
Some experts said that, unlike the national organization of centralized drug procurement, the medical insurance drug catalogue is adjusted more for drugs with high clinical value and high demand, among which innovative drugs have attracted much attention
.
In recent years, Chinese pharmaceutical companies have accelerated the development of innovative drugs, and domestic innovative drugs may usher in the spring of development with the help of medical insurance catalog adjustments
.
.
Some experts said that, unlike the national organization of centralized drug procurement, the medical insurance drug catalogue is adjusted more for drugs with high clinical value and high demand, among which innovative drugs have attracted much attention
.
In recent years, Chinese pharmaceutical companies have accelerated the development of innovative drugs, and domestic innovative drugs may usher in the spring of development with the help of medical insurance catalog adjustments
.
Fifth, it is predicted that the medical insurance catalog may involve the adjustment of drugs and the extent of price reductions
.
According to the "Choice between Entry and Exit, 2021 Medical Insurance Catalogue Adjustments" published by the WeChat public account "Medicine Observer Network", it is predicted that the number of innovative drugs (not including proprietary Chinese medicines) in the 2021 version of the catalogue is expected to be large
.
Products that did not enter the 2019 and 2020 medical insurance catalogues do not have advantages in terms of price.
Therefore, it is predicted that the final drugs imported into the 2021 catalogue will be mostly innovative drugs and innovative biological preparations, as well as some Chinese patent medicines and old products.
Less
.
At the same time, the average price drop is expected to exceed 50%
.
( Liu Yang, Public Opinion Monitoring Center of China Health Media Group)
Medicine medicine medicine health healthy health .
According to the "Choice between Entry and Exit, 2021 Medical Insurance Catalogue Adjustments" published by the WeChat public account "Medicine Observer Network", it is predicted that the number of innovative drugs (not including proprietary Chinese medicines) in the 2021 version of the catalogue is expected to be large
.
Products that did not enter the 2019 and 2020 medical insurance catalogues do not have advantages in terms of price.
Therefore, it is predicted that the final drugs imported into the 2021 catalogue will be mostly innovative drugs and innovative biological preparations, as well as some Chinese patent medicines and old products.
Less
.
At the same time, the average price drop is expected to exceed 50%
.
( Liu Yang, Public Opinion Monitoring Center of China Health Media Group)
